Tittler M, Weinreich P, Seeman P
Proc Natl Acad Sci U S A. 1977 Sep;74(9):3750-3. doi: 10.1073/pnas.74.9.3750.
Because dihydroergocryptine (DHE) and closely related ergots are dopamine-mimetic agonists, we tested [3H]DHE as a possible ligand for [3H]dopamine receptors in the calf caudate. In order to avoid [3H]DHE from tagging alpha-adrenergic receptors, an excess of 500 nM phentolamine was used to block these sites, permitting the dopamine receptors to be measured separately. Specific binding of [3H]DHE was defined as total binding minus that occurring in the presence of 1 muM (+)-butaclamol. Excess phentolamine reduced the specific binding of [3H]DHE from 328 down to 138 fmol/mg, the difference presumably representing alpha-receptors. The KD for [3H]DHE was 0.55 nM (with or without phentolamine), and this high affinity site was blocked (in the presence of phentolamine) by 250nM apomorphine, 650 nM dopamine, and 1200 mM (minus)-norepinephrine, indicating that[3H]DHE was binding to dopamine receptors. All neuroleptics blocked specific [3H]DHE binding in direct relation to the clinical potency of the neuroleptic. The displacement of specific [3H]DHE binding by dopamine or by norepinephrine (in the presence of phentolamine) revealed two subsets of dopamine receptors.
由于二氢麦角隐亭(DHE)及与之密切相关的麦角生物碱是多巴胺模拟激动剂,我们测试了[3H]DHE作为小牛尾状核中[3H]多巴胺受体的一种可能配体。为避免[3H]DHE标记α-肾上腺素能受体,使用过量500 nM的酚妥拉明来阻断这些位点,从而能够分别测定多巴胺受体。[3H]DHE的特异性结合定义为总结合量减去在1 μM(+)-布他拉莫存在时的结合量。过量的酚妥拉明使[3H]DHE的特异性结合从328 fmol/mg降至138 fmol/mg,这一差异大概代表α-受体。[3H]DHE的解离常数(KD)为0.55 nM(无论有无酚妥拉明),并且该高亲和力位点在(存在酚妥拉明的情况下)被250 nM阿扑吗啡、650 nM多巴胺和1200 mM(-)-去甲肾上腺素阻断,表明[3H]DHE与多巴胺受体结合。所有抗精神病药物均与抗精神病药物的临床效力直接相关地阻断[3H]DHE的特异性结合。多巴胺或去甲肾上腺素(在酚妥拉明存在下)对[3H]DHE特异性结合的置换揭示了多巴胺受体的两个亚组。